No, but I don't think they have enough data to support a pharma deal to pay for a phase 3 trial. The market is predicting that there is high chance of BIT landing a significant pharma deal (the fully diluted MC is near $100 million). I think the market is wrong, but I guess we will see over the coming months who is correct.
In my opinion the best chance BIT has is on the HBV front as this an area where some good preclinical data could attract some serious pharma interest. It will be a long slog though.
BIT Price at posting:
11.5¢ Sentiment: Sell Disclosure: Not Held
